[go: up one dir, main page]

DE60333094D1 - Verbindungen, zusammensetzungen und verfahren - Google Patents

Verbindungen, zusammensetzungen und verfahren

Info

Publication number
DE60333094D1
DE60333094D1 DE60333094T DE60333094T DE60333094D1 DE 60333094 D1 DE60333094 D1 DE 60333094D1 DE 60333094 T DE60333094 T DE 60333094T DE 60333094 T DE60333094 T DE 60333094T DE 60333094 D1 DE60333094 D1 DE 60333094D1
Authority
DE
Germany
Prior art keywords
compositions
compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60333094T
Other languages
English (en)
Inventor
Andrew Mcdonald
Gustave Bergnes
Bainian Feng
David J C Morgans Jr
Steven David Knight
Kenneth A Newlander
Dashyant Dhanak
Christopher S Brook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Cytokinetics Inc
Original Assignee
GlaxoSmithKline LLC
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC, Cytokinetics Inc filed Critical GlaxoSmithKline LLC
Application granted granted Critical
Publication of DE60333094D1 publication Critical patent/DE60333094D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE60333094T 2002-04-17 2003-04-11 Verbindungen, zusammensetzungen und verfahren Expired - Lifetime DE60333094D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37345402P 2002-04-17 2002-04-17
US41068202P 2002-09-13 2002-09-13
PCT/US2003/011432 WO2003088903A2 (en) 2002-04-17 2003-04-11 Compounds, compositions, and methods

Publications (1)

Publication Number Publication Date
DE60333094D1 true DE60333094D1 (de) 2010-08-05

Family

ID=29254526

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60333094T Expired - Lifetime DE60333094D1 (de) 2002-04-17 2003-04-11 Verbindungen, zusammensetzungen und verfahren

Country Status (21)

Country Link
US (7) US6924376B2 (de)
EP (1) EP1511734B1 (de)
JP (1) JP4664597B2 (de)
KR (1) KR101052816B1 (de)
CN (1) CN100381437C (de)
AR (1) AR039419A1 (de)
AT (1) ATE471931T1 (de)
AU (1) AU2003234733B2 (de)
BR (1) BR0309278A (de)
CA (1) CA2482041C (de)
DE (1) DE60333094D1 (de)
DK (1) DK1511734T3 (de)
IL (2) IL164581A (de)
MX (1) MXPA04010240A (de)
MY (1) MY140169A (de)
NO (1) NO330433B1 (de)
NZ (1) NZ536190A (de)
PL (1) PL211300B1 (de)
RU (1) RU2308454C9 (de)
TW (1) TWI282337B (de)
WO (1) WO2003088903A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ536190A (en) 2002-04-17 2007-08-31 Cytokinetics Inc Compounds for treating cellular proliferative diseases by modulating the activity of the mitotic kinesin KSP
DE60326248D1 (de) * 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
WO2004024086A2 (en) * 2002-09-13 2004-03-25 Cytokinetics, Inc. Compounds, compositions and methods
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
PT1601673E (pt) * 2003-03-07 2009-07-29 Astrazeneca Ab Heterociclos fundidos e suas utilizações
EP1670456A2 (de) * 2003-10-06 2006-06-21 Cytokinetics, Inc. Verbindungen, zusammensetzungen und verfahren
JP2007527917A (ja) * 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
EP1723119A4 (de) * 2004-03-08 2009-11-25 Wyeth Corp Ionenkanalmodulatoren
WO2005113507A1 (en) * 2004-05-21 2005-12-01 Novartis Vaccines And Diagnostics Inc. Substituted quinoline derivatives as mitotic kinesin inhibitors
US20070287703A1 (en) * 2004-07-22 2007-12-13 Astrazeneca Ab Fused Pyrimidones Useful in the Treatment and the Prevention of Cancer
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
RU2447077C2 (ru) * 2004-08-18 2012-04-10 Астразенека Аб Энантиомеры выбранных конденсированных пиримидинов и их применение для лечения и предотвращения злокачественного новообразования
DE602005017283D1 (de) * 2004-08-18 2009-12-03 Astrazeneca Ab Ausgewählte kondensierte heterocyclen und deren anwendung
WO2006060737A2 (en) * 2004-12-03 2006-06-08 Takeda San Diego, Inc. Mitotic kinesin inhibitors
WO2007067752A2 (en) * 2005-12-08 2007-06-14 Cytokinetics, Inc. Certain compositions and methods of treatment
US20090093641A1 (en) * 2006-03-13 2009-04-09 University Of Florida Research Foundation, Inc. Synthesis of Pentafluorosulfanyl (SF5)-Substituted Heterocycles and Alkynes
WO2007134183A2 (en) * 2006-05-13 2007-11-22 Advanced Technology Materials, Inc. Chemical reagent delivery system utilizing ionic liquid storage medium
MX2009007260A (es) 2007-01-05 2009-07-10 Novartis Ag Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
RS56432B1 (sr) 2009-11-05 2018-01-31 Rhizen Pharmaceuticals S A Novi benzopiran modulatori kinaze
KR102263079B1 (ko) * 2009-11-05 2021-06-10 리젠 파마슈티컬스 소시에떼 아노님 신규한 벤조피란 키나제 조절제
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
MX365160B (es) * 2011-05-04 2019-05-24 Rhizen Pharmaceuticals Sa Compuestos novedosos como moduladores de proteína cinasas.
SG11201408821SA (en) 2012-07-04 2015-01-29 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors
RU2015127822A (ru) * 2012-12-13 2017-01-16 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы энхансера гомолога 2 белка zeste
US9556157B2 (en) 2013-07-10 2017-01-31 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2017015221A1 (en) * 2015-07-23 2017-01-26 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
ES2880766T3 (es) 2016-02-09 2021-11-25 Pharmakea Inc Inhibidores de quinolinona lisil oxidasa similar al tipo 2 y usos de los mismos
CN111991389B (zh) * 2020-09-17 2021-11-23 陕西科技大学 Sb-743921用于制备抗真菌药物的用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US116400A (en) * 1871-06-27 Improvement in heels for boots and shoes
US169159A (en) * 1875-10-26 Improvement in corsets
US55054A (en) * 1866-05-29 Improvement in lamp-chimneys
GB728767A (en) * 1951-10-12 1955-04-27 Wander Ag Dr A 2-substituted chromone compounds, and a method of making same
NL84159C (de) 1952-06-30
EP0020018B1 (de) 1979-05-19 1983-06-01 Beecham Group Plc Chroman-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
EP0046953B1 (de) 1980-08-30 1989-12-06 Hoechst Aktiengesellschaft Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung
US4459420A (en) 1982-05-17 1984-07-10 The Upjohn Company Pyrogallol synthesis of anti-atherogenic furochromones
US4434296A (en) 1982-05-17 1984-02-28 The Upjohn Company Process for preparing intermediates for antiatherosclerotic compounds
US4434295A (en) 1982-05-17 1984-02-28 The Upjohn Company Anti-atherosclerotic 6,7-dihydro-7,7-disubstituted-khellin analogs
US4482558A (en) 1982-06-18 1984-11-13 Pfizer Inc. Antifungal amide and urea derivatives of (3-amino-2-aryl-2-hydroxyprop-1-yl)-1H-1,2,4-triazoles
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
IN164232B (de) 1986-04-11 1989-02-04 Hoechst India
IL85554A0 (en) 1987-03-02 1988-08-31 Takeda Chemical Industries Ltd Chromone derivatives
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
MX13485A (es) * 1987-10-19 1993-05-01 Pfizer Procedimiento para obtener tetralinas, cromados y compuestos relacionados, sustituidos
USH1427H (en) 1988-04-06 1995-04-04 Briet; Phillipe Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2
MA21528A1 (fr) 1988-04-06 1989-12-31 Lipha Composants substituants du flavonoide, leurs sels, leurs manufactures et produits contenant ces matieres .
US5304548A (en) 1988-08-16 1994-04-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5180717A (en) 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
DE3836676A1 (de) 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
FI912995A0 (fi) * 1988-12-21 1991-06-19 Upjohn Co Atiaterosklerotiska och antirombotiska 1-benzopyran-4-oner och 2-amino-1,3-benzoxazin-4-oner.
US5082849A (en) 1989-07-13 1992-01-21 Huang Fu Chich Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4
US4977162A (en) 1989-07-13 1990-12-11 Rorer Pharmaceutical Corporation Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments
US5215989A (en) 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
JPH05509302A (ja) 1990-06-20 1993-12-22 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類
CA2087423A1 (en) 1990-07-25 1992-01-26 Tatsuki Shiota Benzopyran derivative, process for producing the same and pharmaceutical composition containing the same
WO1992006066A1 (en) 1990-09-28 1992-04-16 Ube Industries, Ltd. Process for producing diester of carbonic acid
WO1992006086A1 (en) 1990-10-01 1992-04-16 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
JPH05301813A (ja) 1991-10-15 1993-11-16 Kao Corp 皮膚外用剤
EP0623608B1 (de) 1992-01-24 2001-05-30 Teijin Limited Benzopyran-derivate, deren herstellung sowie diese als aktive bestandteile enthaltende arzneimittel
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
US5605896A (en) 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
FR2693196B1 (fr) 1992-07-03 1994-12-23 Lipha Dérivés de benzopyranone ou de benzothiopyranone, procédé de préparation et composition pharmaceutique les contenant.
JP2579303Y2 (ja) * 1992-08-14 1998-08-27 株式会社共立 バリカン形刈払機
WO1995022992A2 (en) 1994-02-23 1995-08-31 Chiron Corp Method and compositions for increasing the serum half-life of pharmacologically active agents
DE69518322T2 (de) 1994-06-10 2001-02-15 Smithkline Beecham P.L.C., Brentford C-4 amid substituierte verbindungen und deren verwendung als therapeutische mittel
US5607928A (en) 1994-08-05 1997-03-04 Zeneca Limited Carbapenem derivatives containing a bicyclic ketone substituent and their use as anti-infectives
GB9417969D0 (en) 1994-09-07 1994-10-26 King S College London Alkaloids and derivatives thereof
US5602171A (en) 1995-06-07 1997-02-11 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof
AU4153496A (en) 1995-10-20 1997-05-07 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
NL1003520C2 (nl) 1996-07-05 1998-01-07 Stork Amsterdam Sterilisatie-inrichting en werkwijze voor het steriliseren van voorwerpen.
US5908934A (en) 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
JPH10273467A (ja) * 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
GB9807779D0 (en) 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
DE19850131A1 (de) 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
US6087385A (en) 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
US6028088A (en) 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
DE19858341A1 (de) * 1998-12-17 2000-06-21 Merck Patent Gmbh Chromanderivate
US6399633B1 (en) * 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
GB9911071D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
AU7080500A (en) 1999-08-27 2001-03-26 Chemocentryx, Inc. Compounds and methods for modulating cxcr3 function
GB9920910D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel chalcones
GB9920912D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel derivatives of flavones,xanthones and coumarins
DE60017157T2 (de) 1999-09-16 2005-12-22 Curis, Inc., Cambridge Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683095B2 (en) * 2000-05-03 2004-01-27 Lg Life Sciences Ltd. CDK inhibitors having 3-hydroxychromen-4-one structure
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
DE10036003A1 (de) 2000-07-25 2002-02-14 Aventis Cropscience Gmbh Herbizide Mittel
US6903121B1 (en) 2000-08-17 2005-06-07 Allergan, Inc. Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
JP2002322169A (ja) 2001-02-21 2002-11-08 Sankyo Co Ltd クロメン誘導体
KR20040031782A (ko) 2001-07-27 2004-04-13 쿠리스 인코퍼레이션 헤지호그 신호전달 경로의 조절물질, 이를 함유하는조성물 및 이의 용도
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
JP2005511581A (ja) 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
WO2003049679A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
DE60222302T2 (de) 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
WO2003049678A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003050122A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
DE60232994D1 (de) 2001-12-06 2009-08-27 Merck & Co Inc Inhibitoren von mitotischem kinesin
EP1492487B1 (de) 2002-03-08 2009-11-11 Merck & Co., Inc. Mitotische kinesin-hemmer
NZ536190A (en) * 2002-04-17 2007-08-31 Cytokinetics Inc Compounds for treating cellular proliferative diseases by modulating the activity of the mitotic kinesin KSP
EP1509507A4 (de) 2002-05-23 2006-09-13 Merck & Co Inc Inhibitoren von mitotischem kinesin
ES2282647T3 (es) 2002-06-14 2007-10-16 MERCK & CO., INC. Inhibidores de cinesina mitotica.
US7348440B2 (en) 2002-06-14 2008-03-25 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1551962A4 (de) 2002-07-08 2007-08-01 Merck & Co Inc Mitotische kinesin-bindungsstelle
DE60326248D1 (de) 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
AU2003249534A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
WO2004024086A2 (en) * 2002-09-13 2004-03-25 Cytokinetics, Inc. Compounds, compositions and methods
EP1670456A2 (de) 2003-10-06 2006-06-21 Cytokinetics, Inc. Verbindungen, zusammensetzungen und verfahren
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
JP4502322B2 (ja) 2004-11-08 2010-07-14 Ａｇｃテクノグラス株式会社 ガラス管の曲げ加工方法およびその成形用金型

Also Published As

Publication number Publication date
AU2003234733A1 (en) 2003-11-03
CN100381437C (zh) 2008-04-16
JP4664597B2 (ja) 2011-04-06
MY140169A (en) 2009-11-30
TWI282337B (en) 2007-06-11
KR20050036908A (ko) 2005-04-20
NZ536190A (en) 2007-08-31
RU2308454C9 (ru) 2008-05-10
EP1511734A2 (de) 2005-03-09
IL164581A0 (en) 2005-12-18
US8119678B2 (en) 2012-02-21
EP1511734A4 (de) 2006-05-10
MXPA04010240A (es) 2005-06-08
US7491746B2 (en) 2009-02-17
WO2003088903A2 (en) 2003-10-30
PL373577A1 (en) 2005-09-05
US20110230550A1 (en) 2011-09-22
HK1070656A1 (en) 2005-06-24
CN1662508A (zh) 2005-08-31
CA2482041A1 (en) 2003-10-30
US7919524B2 (en) 2011-04-05
US6924376B2 (en) 2005-08-02
NO330433B1 (no) 2011-04-11
AR039419A1 (es) 2005-02-16
US20060020008A1 (en) 2006-01-26
US20130053436A1 (en) 2013-02-28
US20120209012A1 (en) 2012-08-16
US20090005580A1 (en) 2009-01-01
US20040082638A1 (en) 2004-04-29
RU2004133325A (ru) 2005-10-27
CA2482041C (en) 2012-06-05
KR101052816B1 (ko) 2011-07-29
RU2308454C2 (ru) 2007-10-20
US7629477B2 (en) 2009-12-08
ATE471931T1 (de) 2010-07-15
NO20044662L (no) 2005-01-14
AU2003234733B2 (en) 2009-01-29
US8329928B2 (en) 2012-12-11
DK1511734T3 (da) 2010-08-02
US20100105767A1 (en) 2010-04-29
IL164581A (en) 2009-11-18
IL188954A (en) 2011-02-28
JP2005523312A (ja) 2005-08-04
TW200408634A (en) 2004-06-01
WO2003088903A3 (en) 2004-09-30
US8633236B2 (en) 2014-01-21
EP1511734B1 (de) 2010-06-23
PL211300B1 (pl) 2012-05-31
BR0309278A (pt) 2005-04-26

Similar Documents

Publication Publication Date Title
ATE471931T1 (de) Verbindungen, zusammensetzungen und verfahren
ATE332318T1 (de) Mehrzweckpolymere, verfahren und zusammensetzungen
ATE549329T1 (de) Chinazoline verbindungen
EP1633362A4 (de) Verbindungen, verfahren und pharmazeutische zusammensetzungen zur hemmung von parp
EP1628655A4 (de) Antiseptische zusammensetzungen, verfahren und systeme
EP1646382A4 (de) Verbindungen, zusammensetzungen und verfahren
IS7520A (is) Pyrimidínonefnasambönd, samsetningar og aðferðir
DE60210782D1 (de) Glukokinase beeinflussende verbindungen
DE60325255D1 (de) Duftzusammensetzung
AU2003262747A8 (en) Compounds, compositions, and methods
EP1561476A4 (de) Desodorierende zusammensetzung
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
FR2862654B1 (fr) Composition amylacee filmogene
AU2003270015A8 (en) Compounds, compositions, and methods
DE10393374D2 (de) Zusammensetzung
AU2003299612A8 (en) Compounds, compositions and methods
AU2003277079A8 (en) Compounds, compositions, and methods
ATE486859T1 (de) Verbindungen modulierende thrombopoietinaktivität und verfahren
DE602004018936D1 (de) Härtbare zusammensetzung
SE0500163L (sv) Sammansättning
EP1455841A4 (de) Osteopontin-verwandte zusammensetzungen und verfahren
AU2003290507A8 (en) Compounds, compositions and methods
IL167936A0 (en) Compounds, compositions,and methods
ATE405574T1 (de) Aryl-annellierte azapolyzyklische verbindungen